Ignite Creation Date:
2024-05-19 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06419179
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-17
First Post:
2024-05-03
Brief Title:
Maintenance Durvalumab MEDI4736 and Olaparib AZD2281 After Standard 1st Line Treatment CarboplatinCisplatin Etoposide Durvalumab in HRD Positive Extensive Disease ED Small-cell Lung Cancer SCLC
Sponsor:
University of Cologne
Organization:
University of Cologne
Study Overview
Official Title:
A Multicenter Phase II Trial of Maintenance Durvalumab MEDI4736 and Olaparib AZD2281 After Standard 1st Line Treatment CarboplatinCisplatin Etoposide Durvalumab in Homologous Recombination Deficiency HRD Positive Extensive Disease ED Small-cell Lung Cancer SCLC
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GUIDANCE
Brief Summary:
Maintenance durvalumab MEDI4736 and olaparib AZD2281 after standard 1st line treatment carboplatin cisplatin etoposide durvalumab in HRD positive extensive disease ED small-cell lung cancer SCLC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2024-512373-27-00 | CTIS | None | None |